Previous studies have shown that HSP90 inhibitors such as 17-AAG, Ganetespib, and AUY922 significantly suppress AKT/ERK signaling, reduce MYC expression, and enhance radiosensitivity in ESCC models.[47–49] Therefore, a combined strategy integrating BPA exposure control with HSP90-targeted therapy may provide a novel avenue for the prevention and treatment of ESCA. Here, HSP90AA1 is linked to esophageal squamous cell carcinoma.